319926-92-6

Basic information

• Product Name: 1-Boc-4-(3,4-dichlorophenyl)piperazine
• Synonyms: 1-Boc-4-(3,4-dichlorophenyl)piperazine;tert-butyl 4-(3,4-dichlorophenyl)piperazine-1-carboxylate
• CAS NO: 319926-92-6
• Molecular Formula: C₁₅H₂₀Cl₂N₂O₂
• Molecular Weight: 331.2375
• Mol File: 319926-92-6.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1-Boc-4-(3,4-dichlorophenyl)piperazine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Boc-4-(3,4-dichlorophenyl)piperazine(319926-92-6)
• EPA Substance Registry System: 1-Boc-4-(3,4-dichlorophenyl)piperazine(319926-92-6)

Safety Data

• Hazardous Substances Data: 319926-92-6(Hazardous Substances Data)

Usage

Chemical class

Piperazine derivatives

Structure

Piperazine ring with a 3,4-dichlorophenyl group and a tert-butoxycarbonyl (Boc) protecting group attached to the nitrogen atom

Use in research

Pharmaceutical research and development

Role

Acts as a substrate in the synthesis of various biologically active compounds

Pharmacological applications

Interaction with biological targets such as receptors and enzymes

Value

Valuable in the study of new drug candidates

Properties and reactivity

Important intermediate in the synthesis of various pharmaceuticals

Utilization

Commonly used by medicinal chemists and pharmacologists in drug discovery and development

Upstream product

• 18282-59-2 4-bromo-1,2-dichlorobenzene 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 20555-91-3 3,4-dichloroiodobenzene 

Downstream Products

• 57260-67-0 1-(3,4-dichloro)phenylpiperazine 

Relevant articles and documents

Modulation of the Cs2CO3-promoted catalytic amination by a crown ether.

The catalytic addition of 18-Crown-6 in some Cs2CO3-promoted amination of triflates and bromides was beneficial to improve sluggish reaction with suppression of the unwanted side products. The protocol was useful for the preparation of chlorinated aryl piperazines from phenol derivatives.

Optimization of 5-substituted thiazolyl ureas and 6-substituted imidazopyridines as potential HIV-1 latency reversing agents

A persistent latent reservoir of virus in CD4+ T cells is a major barrier to cure HIV. Activating viral transcription in latently infected cells using small molecules is one strategy being explored to eliminate latency. We previously described the use of a FlpIn.FM HEK293 cellular assay to identify and then optimize the 2-acylaminothiazole class to exhibit modest activation of HIV gene expression. Here, we implement two strategies to further improve the activation of viral gene expression and physicochemical properties of this class. Firstly, we explored rigidification of the central oxy-carbon linker with a variety of saturated heterocycles, and secondly, investigated bioisosteric replacement of the 2-acylaminothiazole moiety. The optimization process afforded lead compounds (74 and 91) from the 2-piperazinyl thiazolyl urea and the imidazopyridine class. The lead compounds from each class demonstrate potent activation of HIV gene expression in the FlpIn.FM HEK293 cellular assay (both with LTR EC50s of 80 nM) and in the Jurkat Latency 10.6 cell model (LTR EC50 220 and 320 nM respectively), but consequently activate gene expression non-specifically in the FlpIn.FM HEK293 cellular assay (CMV EC50 70 and 270 nM respectively) manifesting in cellular cytotoxicity. The lead compounds have potential for further development as novel latency reversing agents.